UA118278C2 - Гідроксиформамідні похідні та їх застосування - Google Patents
Гідроксиформамідні похідні та їх застосуванняInfo
- Publication number
- UA118278C2 UA118278C2 UAA201608690A UAA201608690A UA118278C2 UA 118278 C2 UA118278 C2 UA 118278C2 UA A201608690 A UAA201608690 A UA A201608690A UA A201608690 A UAA201608690 A UA A201608690A UA 118278 C2 UA118278 C2 UA 118278C2
- Authority
- UA
- Ukraine
- Prior art keywords
- formamide derivatives
- hydroxy formamide
- tll1
- hydroxy
- tll2
- Prior art date
Links
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 title 1
- 101000637851 Homo sapiens Tolloid-like protein 1 Proteins 0.000 abstract 2
- 101000637850 Homo sapiens Tolloid-like protein 2 Proteins 0.000 abstract 2
- 102100031996 Tolloid-like protein 1 Human genes 0.000 abstract 2
- 102100031997 Tolloid-like protein 2 Human genes 0.000 abstract 2
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 abstract 1
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Розкриті сполуки, що мають формулу: , де R1, R2 і R3 мають значення, визначені в даній заявці, і способи отримання і застосування таких сполук, включаючи застосування як інгібіторів ВМР1, TLL1 та/або TLL2 і для лікування захворювань, пов'язаних з активністю ВМР1, TLL1 та/або TLL2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461925848P | 2014-01-10 | 2014-01-10 | |
PCT/IB2015/050179 WO2015104684A1 (en) | 2014-01-10 | 2015-01-09 | Hydroxy formamide derivatives and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
UA118278C2 true UA118278C2 (uk) | 2018-12-26 |
Family
ID=52440747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201608690A UA118278C2 (uk) | 2014-01-10 | 2015-01-09 | Гідроксиформамідні похідні та їх застосування |
Country Status (21)
Country | Link |
---|---|
US (2) | US10450288B2 (uk) |
EP (1) | EP3092233A1 (uk) |
JP (2) | JP2017507915A (uk) |
KR (1) | KR20160106684A (uk) |
CN (2) | CN106103431B (uk) |
AU (1) | AU2015205370B2 (uk) |
BR (1) | BR112016016130A2 (uk) |
CA (1) | CA2936467A1 (uk) |
CL (1) | CL2016001746A1 (uk) |
CR (1) | CR20160316A (uk) |
DO (1) | DOP2016000170A (uk) |
EA (1) | EA031654B1 (uk) |
IL (1) | IL246653A0 (uk) |
MA (1) | MA39171A1 (uk) |
MX (1) | MX2016009064A (uk) |
PE (1) | PE20160998A1 (uk) |
PH (1) | PH12016501349A1 (uk) |
SG (1) | SG11201605539SA (uk) |
TW (1) | TW201620887A (uk) |
UA (1) | UA118278C2 (uk) |
WO (1) | WO2015104684A1 (uk) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CR20160316A (es) * | 2014-01-10 | 2016-09-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compuestos derivados de hidroxiformamida y usos del mismo |
WO2017006295A1 (en) * | 2015-07-08 | 2017-01-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
JP2018525353A (ja) | 2015-07-09 | 2018-09-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Bmp1、tll1および/またはtll2の阻害剤としての使用するための、n−ヒドロキシホルムアミド化合物およびそれらを含んでなる組成物 |
CN106699604B (zh) * | 2017-01-09 | 2019-01-01 | 四川同晟生物医药有限公司 | 一种沙库比曲及其中间体的制备方法 |
US9862675B1 (en) * | 2017-07-05 | 2018-01-09 | King Fahd University Of Petroleum And Minerals | Method of N-formylating amines with a phosphonic anhydride |
EP4225321A1 (en) * | 2020-10-07 | 2023-08-16 | Venatorx Pharmaceuticals, Inc. | Process for boron-containing compounds |
CN114230463A (zh) * | 2021-12-28 | 2022-03-25 | 青岛科技大学 | 一种邻羟基苯甲酸苯酯的后处理方法 |
CN114195638B (zh) * | 2021-12-28 | 2023-07-14 | 青岛科技大学 | 一种邻羟基苯甲酸苯酯的制备方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US6228982B1 (en) | 1992-05-22 | 2001-05-08 | Benget Norden | Double-stranded peptide nucleic acids |
US6451968B1 (en) | 1991-05-24 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Peptide nucleic acids |
US5641625A (en) | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
GB9311386D0 (en) | 1993-06-02 | 1993-07-21 | Pna Diagnostics As | Nucleic acid analogue assay procedures |
GB2285445A (en) | 1993-12-06 | 1995-07-12 | Pna Diagnostics As | Protecting nucleic acids and methods of analysis |
GB2289677A (en) | 1993-12-06 | 1995-11-29 | Pna Diagnostics As | Labelling of nucleic acid analogue-peptide chimerae |
ES2181799T3 (es) | 1994-10-06 | 2003-03-01 | Isis Pharmaceuticals Inc | Conjugados de acidos peptido nucleicos. |
BR9709370A (pt) | 1996-05-30 | 1999-10-05 | Wisconsin Alumni Res Found | Gene semelhante a tolóide de mamìfero e proteìna. |
US6008017A (en) | 1997-01-02 | 1999-12-28 | Smithkline Beecham Corporation | Human cardiac/brain tolloid-like protein |
US6037139A (en) | 1997-06-03 | 2000-03-14 | Wisconsin Alumni Research Foundation | System for assaying modulators of procollagen maturation |
DE19726427A1 (de) | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
EP0922702A1 (de) | 1997-12-13 | 1999-06-16 | Roche Diagnostics GmbH | Neue Azulenderivate und diese enthaltende Arzneimittel |
EP1068337A2 (en) | 1998-04-03 | 2001-01-17 | Wisconsin Alumni Research Foundation | Mammalian gene encoding tolloid-like protein |
DE19850072A1 (de) | 1998-10-30 | 2000-05-04 | Bayer Ag | Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen |
AU772575B2 (en) * | 1998-12-10 | 2004-04-29 | F. Hoffmann-La Roche Ag | Procollagen C-proteinase inhibitors |
CZ20012294A3 (cs) | 1998-12-22 | 2001-12-12 | F. Hoffmann-La Roche Ag | Sulfonamidové hydroxamáty |
EP1238072A2 (en) | 1999-09-01 | 2002-09-11 | Subsidiary N0. 3, INC. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
WO2001016323A2 (en) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
GB9930570D0 (en) | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
CN101289511A (zh) | 2000-04-11 | 2008-10-22 | 杰南技术公司 | 多价抗体及其应用 |
US7816407B2 (en) | 2000-06-15 | 2010-10-19 | University Of Kentucky Research Foundation | Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders |
EP1335898B1 (en) | 2000-09-29 | 2005-11-23 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
US20050147602A1 (en) | 2000-10-19 | 2005-07-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix |
GB0031321D0 (en) | 2000-12-21 | 2001-02-07 | Pfizer Ltd | Treatment |
GB0108097D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
US6821972B2 (en) * | 2001-03-30 | 2004-11-23 | Pfizer Inc. | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
US20030087273A1 (en) | 2001-06-29 | 2003-05-08 | Holzmayer Tanya A. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
DE10134243A1 (de) | 2001-07-14 | 2003-03-27 | Burchardt Elmar Reinhold | Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen |
JP2005507420A (ja) | 2001-11-01 | 2005-03-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | グリコーゲン合成酵素キナーゼ3β阻害剤としてのアミノベンズアミド誘導体 |
AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
EP1509219A1 (en) | 2002-05-13 | 2005-03-02 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
US20040138118A1 (en) | 2002-09-16 | 2004-07-15 | Neil Wolfman | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
WO2004052919A2 (en) * | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
EP1635815A4 (en) | 2003-06-03 | 2009-03-25 | Beth Israel Hospital | METHOD AND COMPOUNDS FOR TREATING TISSUE TESTS |
US7332485B2 (en) | 2003-07-08 | 2008-02-19 | Smithkline Beecham Corp | Peptide deformylase inhibitors |
EP1701729B1 (en) | 2003-12-31 | 2018-05-02 | Warsaw Orthopedic, Inc. | Improved bone matrix compositions and methods |
WO2006057951A2 (en) | 2004-11-22 | 2006-06-01 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
AU2005318163B2 (en) | 2004-12-21 | 2011-12-01 | Merck Serono Sa | Sulfonyl amino cyclic derivatives and use thereof |
WO2006078717A2 (en) | 2005-01-19 | 2006-07-27 | Beth Israel Deaconess Medical Center | Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis |
WO2007006858A2 (en) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
CN101370525B (zh) | 2005-08-19 | 2013-09-18 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
JP5199109B2 (ja) * | 2005-11-24 | 2013-05-15 | メルク セローノ ソシエテ アノニム | N−ヒドロキシアミド誘導体およびその使用 |
US7850964B2 (en) | 2006-07-21 | 2010-12-14 | Genera Istrazivanja D.O.O. | BMP-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
WO2008024767A2 (en) | 2006-08-21 | 2008-02-28 | Wisconsin Alumni Research Foundation | Method and composition for treating a fibrotic disorder |
EP1932907A1 (en) | 2006-12-12 | 2008-06-18 | Novartis AG | Crystal structure of the catalytic domain of tolloid-like protease 1 and uses thereof |
US20090076062A1 (en) | 2007-09-13 | 2009-03-19 | Juergen Klaus Maibaum | Organic Compounds |
UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
WO2009097893A1 (en) | 2008-02-04 | 2009-08-13 | Proyecto De Biomedicina Cima, S.L. | Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
WO2010059861A1 (en) | 2008-11-20 | 2010-05-27 | University Of Southern California | Compositions and methods to modulate hair growth |
WO2011069149A2 (en) * | 2009-12-04 | 2011-06-09 | Dcb-Usa Llc | Cathepsin s inhibitors |
CN104853773A (zh) | 2012-04-25 | 2015-08-19 | 基因研究公司 | 用于治疗和诊断急性心肌梗死的方法和组合物 |
CR20160316A (es) * | 2014-01-10 | 2016-09-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compuestos derivados de hidroxiformamida y usos del mismo |
WO2017006295A1 (en) | 2015-07-08 | 2017-01-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
JP2018525353A (ja) | 2015-07-09 | 2018-09-06 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Bmp1、tll1および/またはtll2の阻害剤としての使用するための、n−ヒドロキシホルムアミド化合物およびそれらを含んでなる組成物 |
-
2015
- 2015-01-09 CR CR20160316A patent/CR20160316A/es unknown
- 2015-01-09 CA CA2936467A patent/CA2936467A1/en not_active Abandoned
- 2015-01-09 PE PE2016001113A patent/PE20160998A1/es unknown
- 2015-01-09 US US15/110,776 patent/US10450288B2/en not_active Expired - Fee Related
- 2015-01-09 TW TW104100718A patent/TW201620887A/zh unknown
- 2015-01-09 BR BR112016016130A patent/BR112016016130A2/pt not_active Application Discontinuation
- 2015-01-09 JP JP2016545920A patent/JP2017507915A/ja not_active Ceased
- 2015-01-09 CN CN201580013152.8A patent/CN106103431B/zh not_active Expired - Fee Related
- 2015-01-09 MX MX2016009064A patent/MX2016009064A/es unknown
- 2015-01-09 SG SG11201605539SA patent/SG11201605539SA/en unknown
- 2015-01-09 EP EP15702008.2A patent/EP3092233A1/en not_active Withdrawn
- 2015-01-09 EA EA201691412A patent/EA031654B1/ru not_active IP Right Cessation
- 2015-01-09 CN CN201910119933.5A patent/CN109970797A/zh active Pending
- 2015-01-09 AU AU2015205370A patent/AU2015205370B2/en not_active Ceased
- 2015-01-09 UA UAA201608690A patent/UA118278C2/uk unknown
- 2015-01-09 KR KR1020167021496A patent/KR20160106684A/ko not_active Application Discontinuation
- 2015-01-09 WO PCT/IB2015/050179 patent/WO2015104684A1/en active Application Filing
- 2015-01-09 MA MA39171A patent/MA39171A1/fr unknown
-
2016
- 2016-07-07 IL IL246653A patent/IL246653A0/en unknown
- 2016-07-07 PH PH12016501349A patent/PH12016501349A1/en unknown
- 2016-07-07 CL CL2016001746A patent/CL2016001746A1/es unknown
- 2016-07-08 DO DO2016000170A patent/DOP2016000170A/es unknown
-
2019
- 2019-09-03 JP JP2019160658A patent/JP2020011968A/ja active Pending
- 2019-10-17 US US16/655,784 patent/US20200095217A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2020011968A (ja) | 2020-01-23 |
MX2016009064A (es) | 2017-01-23 |
CA2936467A1 (en) | 2015-07-16 |
WO2015104684A1 (en) | 2015-07-16 |
US20200095217A1 (en) | 2020-03-26 |
US20160340328A1 (en) | 2016-11-24 |
EP3092233A1 (en) | 2016-11-16 |
IL246653A0 (en) | 2016-08-31 |
AU2015205370A1 (en) | 2016-07-21 |
MA39171A1 (fr) | 2017-07-31 |
JP2017507915A (ja) | 2017-03-23 |
US10450288B2 (en) | 2019-10-22 |
AU2015205370B2 (en) | 2017-11-30 |
BR112016016130A2 (pt) | 2017-08-08 |
CR20160316A (es) | 2016-09-19 |
CN106103431A (zh) | 2016-11-09 |
PH12016501349A1 (en) | 2016-08-15 |
EA201691412A1 (ru) | 2016-12-30 |
KR20160106684A (ko) | 2016-09-12 |
PE20160998A1 (es) | 2016-10-26 |
TW201620887A (zh) | 2016-06-16 |
DOP2016000170A (es) | 2016-10-30 |
CN106103431B (zh) | 2019-03-15 |
SG11201605539SA (en) | 2016-08-30 |
EA031654B1 (ru) | 2019-02-28 |
CN109970797A (zh) | 2019-07-05 |
CL2016001746A1 (es) | 2017-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501349A1 (en) | Hydroxy formamide derivatives and their use | |
PH12017501780A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
IL246564A (en) | 3-aryl-1-heterocyclic-pyrazolo [4,3- d] pyrimidine derivatives and their use in the treatment of diseases | |
MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
CL2016001895A1 (es) | Compuestos | |
MX2016006432A (es) | Tetrahidro-benzodiazepinonas. | |
MX367897B (es) | Derivados de piridazinona macrociclicos. | |
MX2021007268A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
MX364486B (es) | Derivados de piridazinona-amidas. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
MX2018004664A (es) | Antagonistas de ep4. | |
EP4289822A3 (en) | Benzoimidazol-1,2-yl amides as kv7 channel activators | |
MX2016009251A (es) | Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos. | |
BR112017023432A2 (pt) | Derivados de ácido propiônico tetra- hidronaftiridinila e usos do mesmo | |
PH12017501071A1 (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
MY186475A (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
EA201650085A1 (ru) | Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида |